Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cellular Biomedicine (CBMG)

Cellular Biomedicine (CBMG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 263,210
  • Shares Outstanding, K 18,090
  • Annual Sales, $ 220 K
  • Annual Income, $ -38,940 K
  • 60-Month Beta 2.70
  • Price/Sales 1,210.58
  • Price/Cash Flow N/A
  • Price/Book 2.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.53
  • Number of Estimates 2
  • High Estimate -0.50
  • Low Estimate -0.55
  • Prior Year -0.53
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.78 +4.50%
on 06/17/19
17.50 -17.71%
on 06/04/19
-2.66 (-15.59%)
since 05/24/19
3-Month
13.78 +4.50%
on 06/17/19
17.94 -19.73%
on 04/23/19
-2.54 (-14.99%)
since 03/26/19
52-Week
12.04 +19.60%
on 10/26/18
25.00 -42.40%
on 09/27/18
-4.95 (-25.58%)
since 06/26/18

Most Recent Stories

More News
Cellular Biomedicine Group to Present at B. Riley FBR Annual Investor Conference

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

CBMG : 14.56 (+0.07%)
Report: Exploring Fundamental Drivers Behind Wabco, Hollysys Automation Technologies, Cellular Biomedicine Group, and Spectrum Brands -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wabco Holdings Inc. (NYSE:WBC),...

SPB : 53.19 (-1.43%)
HOLI : 18.87 (+2.39%)
CBMG : 14.56 (+0.07%)
WBC : 131.99 (-0.18%)
Cellular Biomedicine: 1Q Earnings Snapshot

CUPERTINO, Calif. (AP) _ Cellular Biomedicine Group Inc. (CBMG) on Tuesday reported a loss of $9.3 million in its first quarter.

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative...

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group to Report First Quarter 2019 Results and Host Conference Call on May 1, 2019

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative...

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group Upgraded to NASDAQ Global Select Market

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group to Participate in Asia Pharma R&D Leaders Summit 2019

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

CBMG : 14.56 (+0.07%)
Cellular Biomedicine Group to Present at Annual BioCentury Future Leaders in the Biotech Industry Conference

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

CBMG : 14.56 (+0.07%)
SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors...

LNTH : 26.64 (-4.03%)
CBMG : 14.56 (+0.07%)
KEG : 2.16 (+11.34%)
PFS : 23.87 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBMG with:

Business Summary

Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments...

See More

Key Turning Points

2nd Resistance Point 16.35
1st Resistance Point 15.45
Last Price 14.56
1st Support Level 14.08
2nd Support Level 13.61

See More

52-Week High 25.00
Fibonacci 61.8% 20.05
Fibonacci 50% 18.52
Fibonacci 38.2% 16.99
Last Price 14.56
52-Week Low 12.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar